Across TCGA pan-cancer cohorts, NDUFA4L2 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated NDUFA4L2 data layer compared with 27 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in sarcoma (SARC), where higher NDUFA4L2 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NDUFA4L2 expression acts as an unfavorable survival marker.

SARC, PRAD, and UCEC are the cancer types where NDUFA4L2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
SARC	OS	Median	All	0.029	0.839	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

Exploration

Same gene, other analysis: NDUFA4L2 tumor-vs-normal RNA expression · all NDUFA4L2 data types